Study to Evaluate the Safety, Tolerability, and PK of Pacritinib

NCT05552183 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Impairment

Interventions

DRUG: oral dose of 200 mg pacritinib twice daily (BID)

Sponsor

CTI BioPharma

Collaborators

[object Object]